| Literature DB >> 25431922 |
Seahyoung Lee1, Eunhyun Choi2, Min-Ji Cha3, Ki-Chul Hwang4.
Abstract
Atrial fibrillation (AF) has been recognized as a major cause of cardiovascular-related morbidity and mortality. MicroRNAs (miRNAs) represent recent additions to the collection of biomolecules involved in arrhythmogenesis. Reactive oxygen species (ROS) have been independently linked to both AF and miRNA regulation. However, no attempts have been made to investigate the possibility of a framework composed of ROS-miRNA-AF that is related to arrhythmia development. Therefore, this review was designed as an attempt to offer a new approach to understanding AF pathogenesis. The aim of this review was to find and to summarize possible connections that exist among AF, miRNAs and ROS to understand the interactions among the molecular entities underlying arrhythmia development in the hopes of finding unappreciated mechanisms of AF. These findings may lead us to innovative therapies for AF, which can be a life-threatening heart condition. A systemic literature review indicated that miRNAs associated with AF might be regulated by ROS, suggesting the possibility that miRNAs translate cellular stressors, such as ROS, into AF pathogenesis. Further studies with a more appropriate experimental design to either prove or disprove the existence of an ROS-miRNA-AF framework are strongly encouraged.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25431922 PMCID: PMC4284676 DOI: 10.3390/ijms151221754
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
miRNAs with reported or possible associations with atrial fibrillation (AF).
| miRNA | Changes in CVDs (Ref. if miR Expression Was Confirmed in Other Study) | Targeted Protein (mRNA) and Subsequent Results | Ref. | |
|---|---|---|---|---|
| Decreased in AF | Potassium channel, inwardly rectifying, Kir2.1 (KCNJ2) | Increased | [ | |
| Decreased in hypertrophy | Connexin 43 (GJA1) | Cx43 displacement due to hyper-phosphorylation | [ | |
| Increased in HF ([ | Protein phosphatase 2A (PPP2CA) | Excessive RyR2 phosphorylation by CaMKII | [ | |
| Increased in AF ([ | Phosphatase and tensin homolog (PTEN) | Increased hypertrophy | [ | |
| Connexin 43 (GJA1) | Disturbed electrical coupling | |||
| Increased in MI Increased in AF | Sprouty1 (SPRY1) | Increased fibrosis | [ | |
| Calcium channel, voltage-dependent, | Shortened APD | [ | ||
| Calcium channel, voltage-dependent, beta 2 subunit (CACNB2) | Decreased | |||
| Decreased in AF | Potassium channel, inwardly rectifying, Kir2.1 (KCNJ2) | Increased | [ | |
| Decreased in CHF | Collagen, type I, alpha 1 (COL1A1) | Increased fibrosis | [ | |
| Collagen, type III, alpha 1 (COL3A1) | ||||
| Fibrillin (FBN) | ||||
| Reduced in AF ([ | Connective tissue growth factor (CTGF) | Increased fibrosis | [ | |
| Increased in Atherosclerosis ([ | Connexin 43 (GJA1) | Disturbed electrical coupling | [ | |
| Reduced in AF ([ | Connective tissue growth factor (CTGF) | Increased fibrosis | [ | |
| Increased in HF ([ | Protein phosphatase 2A (PPP2CA) | Excessive RyR2 phosphorylation by CaMKII | [ | |
| Decreased in AF ([ | Ca2+/calmodulin-dependent protein kinase 2 delta (CAMK2D) | Excessive RyR2 phosphorylation by CaMKII | [ | |
| Increased in AF | Calcium channel, voltage-dependent, | Shortened APD | [ | |
| Increased in hypertrophy ([
| Calcium channel, voltage-dependent, beta 1 subunit (CACNB1) | Decreased | [ | |
| Increased in AF | Small-conductance calcium-activated potassium channel 3 (KCNN3) | Altered conduction | [ | |
| Increased in hypertrophy ([ | Increased AF | |||
| Decreased in Acute MI | Beta 1 adrenergic receptor (ADRB1) | Increased arrhythmia score | [ | |
AF, atrial fibrillation; HF, heart failure; MI, myocardial infarction; CHF, congestive heart failure; APD, action potential duration.
Modulation of AF-related miRNAs by ROS.
| miRNA | Modulation by ROS | Stimulation | Experimental System | Ref. |
|---|---|---|---|---|
| miR-1 | Increased | H2O2 (50–400 µM) | H9c2 | [ |
| Increased | H2O2 (100 µM, 6 h) | NRCM | [ | |
| Decreased | H2O2 (100 µM, 6 h) | NRVM | [ | |
| miR-19a | Decreased | H2O2 (200 µM, 6 h) | VSMC | [ |
| miR-21 | Increased | H2O2 (10–100 µM, 6 h) | NRCM | [ |
| Increased | H2O2 (25–200 µM, 6 h) | VSMC | [ | |
| Increased | H2O2 (100 µM, 6 h) | NRVM | [ | |
| miR-26 | Increased | H2O2 (100 µM, 6 h) | NRCM | [ |
| Decreased | H2O2 (200 µM, 6 h) | VSMC | [ | |
| miR-29b | Decreased | H2O2 (200 µM, 6 h) | VSMC | [ |
| miR-30 | Decreased | H2O2 (100 µM, 6 h) | NRCM | [ |
| miR-130a | Decreased | H2O2 (200 µM, 6 h) | VSMC | [ |
| miR-133 | Decreased | H2O2 (100 µM, 24 h) | NRCM | [ |
| Decreased | H2O2 (100 µM, 6 h) | NRVM | [ | |
| miR-145 | Decreased | H2O2 (50 µM, 0.5–8 h) | NRVM | [ |
| miR-328 | Decreased | H2O2 (200 µM, 6 h) | VSMC | [ |
| miR-499 | Increased | H2O2 (50–200 µM, 6 h) | NRVM | [ |
| Let-7e | Decreased | H2O2 (50 µM, 1 h) | HCT116 colon cancer cells | [ |
| Increased | H2O2 (200 µM, 6 h) | VSMC | [ |
NRCM, neonatal rat cardiomyocytes; VSMC, vascular smooth muscle cells; NRVM, neonatal rat ventricular myocytes.
Figure 1Concept of the ROS–miRNA–AF framework.